DrugPatentWatch Database Preview

Neopharma Company Profile

« Back to Dashboard

What is the competitive landscape for NEOPHARMA, and when can generic versions of NEOPHARMA drugs launch?

NEOPHARMA has twenty approved drugs.

There are five US patents protecting NEOPHARMA drugs.

There are ninety-three patent family members on NEOPHARMA drugs in forty-eight countries and twenty-four supplementary protection certificates in eight countries.

Summary for Neopharma

International Patents:	93
US Patents:	5
Tradenames:	16
Ingredients:	8
NDAs:	20

Drugs and US Patents for Neopharma

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Neopharma	ALENDRONATE SODIUM	alendronate sodium	TABLET;ORAL	079049-004	Aug 4, 2008	AB	RX	No	No
Neopharma	AUGMENTIN XR	amoxicillin; clavulanate potassium	TABLET, EXTENDED RELEASE;ORAL	050785-001	Sep 25, 2002	AB	RX	Yes	Yes	7,217,430		Y
Neopharma	LAROTID	amoxicillin	FOR SUSPENSION;ORAL	062226-003	Approved Prior to Jan 1, 1982	AB	RX	No	No
Neopharma	AMOXIL	amoxicillin	FOR SUSPENSION;ORAL	050760-002	Apr 15, 1999		DISCN	Yes	No
Neopharma	IRBESARTAN	irbesartan	TABLET;ORAL	203161-003	Sep 27, 2012	AB	RX	No	No
Neopharma	LAROTID	amoxicillin	FOR SUSPENSION;ORAL	062226-004	Approved Prior to Jan 1, 1982	AB	RX	No	No
Neopharma	AUGMENTIN '125'	amoxicillin; clavulanate potassium	TABLET, CHEWABLE;ORAL	050597-001	Jul 22, 1985		DISCN	Yes	No

Paragraph IV (Patent) Challenges for NEOPHARMA drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Extended-release Tablets	1000 mg/62.5 mg		2009-01-21

International Patents for Neopharma Drugs

Country	Patent Number	Estimated Expiration
United Kingdom	0008923
Turkey	200102963
Norway	20014960
Denmark	1044680
Czech Republic	298801
Brazil	0009718
Australia	767177

Supplementary Protection Certificates for Neopharma Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0454511	SPC/GB99/008	United Kingdom		PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015
0296749	SPC/GB96/004	United Kingdom		PRODUCT NAME: ANASTROZOLE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT; REGISTRATION NO/DATE: UK 12619/0106 19950811
0454511	98C0028	Belgium		PRODUCT NAME: IRBESARTAN; NATL. REGISTRATION NO/DATE: EU/1/97/046/001 19970827; FIRST REGISTRATION: CH 54250 02 19970815
1175904	2007C/048	Belgium		PRODUCT NAME: ALENDRONATE DE SODIUM/COLECALCIFEROL; AUTHORISATION NUMBER AND DATE: EU/1/05/310/001 20050826
1174135	SPC/GB10/011	United Kingdom		PRODUCT NAME: THE COMBINATION OF PIOGLITAZONE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY THE HYDROCHLORIDE SALT, AND GLIMEPIRIDE.; REGISTERED: UK EU/1/06/366/001 20070108; UK EU/1/06/366/002 20070108; UK EU/1/06/366/003 20070108; UK EU/1/06/366/004 20070108; UK EU/1/06/366/005 20070108; UK EU/1/06/366/006 20070108; UK EU/1/06/366/019 20070108; UK EU/1/06/366/020 20070108; UK EU/1/06/366/021 20070108; UK EU/1/06/366/022 20070108; UK EU/1/06/366/013 20070108; UK EU/1/06/366/014 20070108; UK EU/1/06/366/015 20070108; UK EU/1/06/366/016 20070108; UK EU/1/06/366/017 20070108; UK EU/1/06/366/018 20070108; UK EU/1/06/366/007 20070108; UK EU/1/06/366/008 20070108; UK EU
1746976	300885	Netherlands		PRODUCT NAME: ONIVYDE - IRINOTECAN; REGISTRATION NO/DATE: EU/1/16/1130 20161018
0454511	10/1999	Austria		PRODUCT NAME: ''IRBESARTAN'' ZUSAMMEN MIT ''HYDROCHLOROTHIAZID''; REGISTRATION NO/DATE: EU/1/98/086/001 - EU/1/98/086/006 19981015

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Neopharma